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the need to establish effective strategies for AF. Clinical outcomes from the ATHENA 
study adapted to Slovak conditions show the actual potential of dronedaron to be 
a cost-effective way in reducing AF complications and decreasing health care 
expenditures.
PCV58
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OBJECTIVES: Cardiac Multi-Slice Computed Tomography (MSCT) has been dem-
onstrated as a valid diagnostic tool for coronary artery disease (CAD) especially due 
to its higher comparative accuracy. Consequently, there is mutual agreement on its 
use following a non-interpretable or equivocal stress-test (exercise, perfusion or stress-
echo) result; however, its frequent use as ﬁrst-step investigation contributes to the 
controversy on which strategy really maximizes patient outcomes. Using data of a 
regional registry, we investigated the optimal application of MSCT in patients with 
suspected CAD. METHODS: During 2007, 566 patients with suspected CAD or stable 
angina underwent MSTC in six different public structures in Emilia-Romagna; after 
applying exclusion criteria (previous hospitalization for Acute Myocardial Infarction 
and/or revascularization; MSCT performed in inpatient setting), 350 subjects (209 
with and 141 without a previous stress-test result, respectively) were considered eligi-
ble. All events of interest, such as death, hospitalizations, diagnostic procedures, visits 
and cardiovascular drugs utilization were traced for one year. Direct costs were evalu-
ated from the perspective of the Regional Health Service (RHS). RESULTS: Except 
for hyperlipidemia (p  0.0058) and diuretics consumption (p = 0.006), all baseline 
characteristics were similar between the two groups. No relevant differences were 
found in all endpoints except for the average number of cardiovascular-related hospi-
talizations (0.46 vs. 0.33; p  0.0013), which was signiﬁcantly lower in the 
“stresstestMSCT” group. Notably, hospitalizations alone accounted for 90% of total 
health care expenditures (a1.018.054 for all 350 patients). The sensitivity analysis 
(based on 5000 bootstrap samples) indicated a mean cost difference of a513 / 22 
(CI 95%) and a mean hospitalizations difference of 0.13 / 0.003 in favor of the 
“stresstestMSCT” strategy (0.46 vs. 0.33; p = 0.66), which showed a probability of 
being cost effective of 0.86 (WTP  a10,000). CONCLUSIONS: Using MSTC after 
stress-test is likely to reduce the risk of hospitalization and additionally provides good 
value for money from the perspective of the RHS.
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COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BETA 
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OBJECTIVES: Chronic heart failure (CHF) is a major health issue because of its 
growing prevalence, morbimortality and associated resource consumption. Beta block-
ers have been shown to be effective and cost-effective therapies for CHF. The aim is 
determining what beta blocker constitutes the most efﬁcient therapy for CHF patients 
in Spain. METHODS: Systematic review of primary (clinical trials) and secondary 
(meta-analyses, clinical practice guidelines, economic assessments and reports from 
independent local agencies) evidence on beta blockers for CHF issued before April 
2009. Once that efﬁcacy of each beta blocker was established, local drug databases 
were accessed in order to estimate the updated annual cost of each therapy and daily 
dose in Spain. RESULTS: Given their similar efﬁcacy [death RR: bisoprolol: 0.66, 
p  0.0001; metoprolol: 0.66, p  0.0001; carvedilol: 0.65, p  0.005, nebivolol: 0.88, 
p  0.21] and safety proﬁles, international clinical guidelines on Cardiology recom-
mend bisoprolol, metoprolol, carvedilol and nebivolol as ﬁrst choice therapies for CHF 
(class I and level of evidence A). Signiﬁcant annual drug cost differences for bisoprolol 
have been previously reported by independent Spanish agency GENESIS and are con-
ﬁrmed with 2009 prices [bisoprolol: a22.36–114.58; metoprolol: a30.20–241.63; 
carvedilol: a39.24–264.62; nebivolol: a52.50–420.01]. When hospitalization costs are 
included, a recent meta-analysis of beta blockers for CHF in Spain proved that biso-
prolol is not only the cheapest beta blocker therapy but even a more efﬁcient alterna-
tive than placebo [2005 prices: bisoprolol: a414.28; metoprolol: a507.64; carvedilol: 
a888.50; placebo: a484.96]. Budget impact analysis yields that bisoprolol implies a 
saving of 26–53% of metoprolol cost of therapy per year and patient, 43–57% when 
compared to carvedilol and 57–73% versus nebivolol. CONCLUSIONS: According 
to recently updated Cardiology guidelines and evidence issued by independent bodies, 
bisoprolol gathers pharmacologic, legal and pharmacoeconomic characteristics that 
conﬁrm their being the most efﬁcient beta blocker (both in terms of cost-beneﬁt and 
cost-effectiveness) for CHF patients in Spain.
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OBJECTIVES: For patients with acute coronary syndrome (ACS) treated with percu-
taneous coronary intervention, 12-month dual antiplatelet (thienopyridine plus 
aspirin) treatment is recommended. A phase III clinical trial (TRITON) in ACS patients 
with planned PCI demonstrated superiority of prasugrel versus clopidogrel on the 
primary composite endpoint (myocardial infarction, stroke, cardiovascular death) but 
also higher bleeding risk. This model was designed to estimate the impact on the hos-
pital budget of the national health insurance of substituting prasugrel to clopidogrel. 
METHODS: The budget impact model was based on index and recurrent hospital 
stays related to cardiovascular and bleeding causes from the economic cohort of 
TRITON (N  6705) with a mean of 380 days of follow-up. A speciﬁc DRG code 
was attributed to each stay and transcoded to French DRG. A weighted cost was cal-
culated based on public and private French DRG ofﬁcial tariff (2007), including an 
average cost for stents and intensive care unit costs. In-hospital costs of thyenopyridine 
use were not included in the analysis. The time horizon was 1-year. Budget impacts 
were calculated for two groups: A) Patients without history of transient ischemic 
attack (TIA) and stroke), B) Patients without TIA/stroke and weight 60 kg and 75 
years-old. RESULTS: For Group A the costs for all patients for one year were 
a25,719,447.48 for prasugrel and a26,123,027.37 for clopidogrel, for Group B they 
were respectively a20,897,133.23a and a21,096,756.42. Predominant differences 
were on costs related to recurrent hospital stays (respectively for A: a5,501,347.76 
and a6,053,118.09a; B: 4,354,983.17 and 4,827,315.74). Substituting prasugrel to 
clopidogrel would result in daily savings of: A) a0.45 per patient B) 0.46a per patient. 
CONCLUSIONS: This budget impact model showed that prevention of recurrent 
events with prasugrel generates savings that could offset to some extent potential price 
differences with clopidogrel.
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OBJECTIVES: The HF-ACTION study was a controlled trial to evaluate efﬁcacy and 
safety of exercise training in patients with heart failure. A prospective economic evalu-
ation was planned alongside the trial to evaluate resource use and costs associated 
with exercise training. METHODS: Between April 2003 and February 2007, HF-
ACTION randomized 2331 heart failure patients with NYHA Class II to IV to usual 
care plus exercise training, consisting of 36 supervised sessions followed by home-
based training, versus usual care alone. Data on medical resource use and hospital 
bills were collected throughout the trial. Intervention-related costs were estimated 
using patient-level data from the trial, administrative records, and published unit costs. 
Counts of resource use were compared using negative binomial regression models. 
Conﬁdence intervals for cost differences were derived using nonparametric bootstrap-
ping. RESULTS: Mean follow-up was 2.5 years in both groups. There were 2297 
hospitalizations in the exercise training group (n  1159) and 2332 in the usual care 
group (n  1172)(P  0.924). The mean number of inpatient days was 13.6 (SD  
27.0) and15.0 (SD  31.4) days in the exercise training and usual care groups, respec-
tively (P  0.21). Additional measures of medical resource use, including urgent care 
visits, outpatient visits and procedures, home IV therapy, skilled nursing and rehabili-
tative care were similar between groups, with the exception that fewer patients in the 
exercise training group underwent high-cost inpatient procedures including heart 
transplant and/or placement of a left ventricular assist device (n  44 [3.7%] vs. 
n  31 [2.7%], P  0.14). Total direct medical costs were estimated at $50,857 (SD  
81,488) in the exercise training group and $56,177 (SD  92,749) in the usual care 
group (95% CI for difference: $12,755 to $1547). Direct cost of exercise training 
was estimated at $1006 (SD  337). CONCLUSIONS: Exercise training had little 
systematic impact on medical resource use overall, but the cost of exercise training 
may have been offset through a reduction in high-cost procedures.
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OBJECTIVES: Estimate annual direct costs for privately-insured U.S. pulmonary 
arterial hypertension (PAH) patients and matched controls. METHODS: From a pri-
vately-insured claims database (8 million beneﬁciaries, 2002–2007), 951 PAH 
